|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:CEO
|
K. Nithyananda Reddy
|
|
gptkbp:country
|
gptkb:India
|
|
gptkbp:exportedTo
|
gptkb:Europe
gptkb:United_States
other international markets
|
|
gptkbp:foundedYear
|
1986
|
|
gptkbp:founder
|
gptkb:K._Nityananda_Reddy
gptkb:P._V._Ramprasad_Reddy
|
|
gptkbp:fullName
|
gptkb:Aurobindo_Pharma_Limited
|
|
gptkbp:headquartersLocation
|
gptkb:Hyderabad
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AUROPHARMA
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
INE406A01037
|
|
gptkbp:listedOn
|
gptkb:NSE
BSE
|
|
gptkbp:manufacturingFacilities
|
gptkb:Argentina
gptkb:Australia
gptkb:Austria
gptkb:Belgium
gptkb:Brazil
gptkb:Canada
gptkb:Chile
gptkb:China
gptkb:Colombia
gptkb:Czech_Republic
gptkb:Denmark
gptkb:Egypt
gptkb:Finland
gptkb:France
gptkb:Germany
gptkb:Greece
gptkb:Hungary
gptkb:India
gptkb:Indonesia
gptkb:Ireland
gptkb:Italy
gptkb:Japan
gptkb:Kenya
gptkb:Malaysia
gptkb:Malta
gptkb:Mexico
gptkb:Morocco
gptkb:Netherlands
gptkb:New_Zealand
gptkb:Nigeria
gptkb:Norway
gptkb:Peru
gptkb:Philippines
gptkb:Poland
gptkb:Portugal
gptkb:Romania
gptkb:Russia
gptkb:Saudi_Arabia
gptkb:Singapore
gptkb:Slovakia
gptkb:South_Africa
gptkb:South_Korea
gptkb:Spain
gptkb:Sweden
gptkb:Switzerland
gptkb:Thailand
gptkb:Turkey
gptkb:Ukraine
gptkb:United_Kingdom
gptkb:United_States
gptkb:Venezuela
gptkb:Vietnam
UAE
|
|
gptkbp:marketCap
|
large cap
|
|
gptkbp:netProfitFY2023
|
INR 2,113 crore
|
|
gptkbp:numberOfEmployees
|
over 23,000
|
|
gptkbp:operatesIn
|
global
|
|
gptkbp:products
|
active pharmaceutical ingredients
generic pharmaceuticals
|
|
gptkbp:revenueFY2023
|
INR 24,855 crore
|
|
gptkbp:stockExchange
|
gptkb:AUROPHARMA
524804
|
|
gptkbp:stockSymbol
|
gptkb:AUROPHARMA
|
|
gptkbp:subsidiary
|
Auro Peptides Ltd.
AuroLife Pharma LLC
Aurobindo Pharma USA Inc.
|
|
gptkbp:website
|
https://www.aurobindo.com/
|
|
gptkbp:bfsParent
|
gptkb:Aurobindo_Pharma
|
|
gptkbp:bfsLayer
|
6
|